175 related articles for article (PubMed ID: 37870954)
1. Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ: A Randomized Clinical Trial.
Khan SA; Mi X; Xu Y; Blanco LZ; Akasha AM; Pilewskie M; Degnim AC; AlHilli Z; Amin AL; Hwang ES; Guenther JM; Kocherginsky M; Benante K; Zhang S; Helland T; Hustad SS; Gursel DB; Mellgren G; Dimond E; Perloff M; Heckman-Stoddard BM; Lee O
JAMA Surg; 2023 Dec; 158(12):1265-1273. PubMed ID: 37870954
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.
Lee O; Page K; Ivancic D; Helenowski I; Parini V; Sullivan ME; Margenthaler JA; Chatterton RT; Jovanovic B; Dunn BK; Heckman-Stoddard BM; Foster K; Muzzio M; Shklovskaya J; Skripkauskas S; Kulesza P; Green D; Hansen NM; Bethke KP; Jeruss JS; Bergan R; Khan SA
Clin Cancer Res; 2014 Jul; 20(14):3672-82. PubMed ID: 25028506
[TBL] [Abstract][Full Text] [Related]
3. Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation.
Lee O; Ivancic D; Allu S; Shidfar A; Kenney K; Helenowski I; Sullivan ME; Muzzio M; Scholtens D; Chatterton RT; Bethke KP; Hansen NM; Khan SA
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1235-46. PubMed ID: 26560487
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial).
Kuo SH; Tseng LM; Chen ST; Sagara Y; Chang YC; Yeh HT; Kuo YL; Hung CC; Lu TP; Lee YH; Toi M; Huang CS
BMC Cancer; 2023 Sep; 23(1):865. PubMed ID: 37710198
[TBL] [Abstract][Full Text] [Related]
5. Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial.
DeCensi A; Puntoni M; Guerrieri-Gonzaga A; Cazzaniga M; Serrano D; Lazzeroni M; Vingiani A; Gentilini O; Petrera M; Viale G; Cuzick J; Bonanni B; Pruneri G
Cancer Prev Res (Phila); 2015 Oct; 8(10):888-94. PubMed ID: 26276754
[TBL] [Abstract][Full Text] [Related]
6. Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.
Guerrieri-Gonzaga A; Sestak I; Lazzeroni M; Serrano D; Rotmensz N; Cazzaniga M; Varricchio C; Pruneri G; Leonardi MC; Orecchia R; Galimberti V; Bonanni B; DeCensi A
Int J Cancer; 2016 Nov; 139(9):2127-34. PubMed ID: 27381855
[TBL] [Abstract][Full Text] [Related]
7. Postoperative tamoxifen for ductal carcinoma in situ.
Staley H; McCallum I; Bruce J
Cochrane Database Syst Rev; 2012 Oct; 10():CD007847. PubMed ID: 23076938
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T
J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Emu Oil Transfersomes for Local Transdermal Delivery of 4-OH Tamoxifen in the Treatment of Breast Cancer.
Sundralingam U; Chakravarthi S; Radhakrishnan AK; Muniyandy S; Palanisamy UD
Pharmaceutics; 2020 Aug; 12(9):. PubMed ID: 32854385
[TBL] [Abstract][Full Text] [Related]
10. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.
Cuzick J; Sestak I; Pinder SE; Ellis IO; Forsyth S; Bundred NJ; Forbes JF; Bishop H; Fentiman IS; George WD
Lancet Oncol; 2011 Jan; 12(1):21-9. PubMed ID: 21145284
[TBL] [Abstract][Full Text] [Related]
11. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.
Hird RB; Chang A; Cimmino V; Diehl K; Sabel M; Kleer C; Helvie M; Schott A; Young J; Hayes D; Newman L
Cancer; 2006 May; 106(10):2113-8. PubMed ID: 16596655
[TBL] [Abstract][Full Text] [Related]
12. Review: Patient-controlled transdermal 4-hydroxytamoxifen (4-OHT) vs. oral tamoxifen: A systematic review and meta analysis.
Sundralingam U; Khan TM; Elendran S; Muniyandy S; Palanisamy UD
Pak J Pharm Sci; 2019 May; 32(3):1121-1128. PubMed ID: 31278729
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis.
Staley H; McCallum I; Bruce J
Breast; 2014 Oct; 23(5):546-51. PubMed ID: 25023044
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
Wapnir IL; Dignam JJ; Fisher B; Mamounas EP; Anderson SJ; Julian TB; Land SR; Margolese RG; Swain SM; Costantino JP; Wolmark N
J Natl Cancer Inst; 2011 Mar; 103(6):478-88. PubMed ID: 21398619
[TBL] [Abstract][Full Text] [Related]
16. A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy: Evaluation of dermal safety, intra-mammary drug distribution, and biologic effects.
Lee O; Bazzi LA; Xu Y; Pearson E; Wang M; Hosseini O; Akasha AM; Choi JN; Karlan S; Pilewskie M; Kocherginsky M; Benante K; Helland T; Mellgren G; Dimond E; Perloff M; Heckman-Stoddard BM; Khan SA
Biomed Pharmacother; 2024 Feb; 171():116105. PubMed ID: 38171245
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen Initiation After Ductal Carcinoma In Situ.
Nichols HB; Bowles EJ; Islam J; Madziwa L; Stürmer T; Tran DT; Buist DS
Oncologist; 2016 Feb; 21(2):134-40. PubMed ID: 26768485
[TBL] [Abstract][Full Text] [Related]
18. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.
Lazzeroni M; Puntoni M; Guerrieri-Gonzaga A; Serrano D; Boni L; Buttiron Webber T; Fava M; Briata IM; Giordano L; Digennaro M; Cortesi L; Falcini F; Serra P; Avino F; Millo F; Cagossi K; Gallerani E; De Simone A; Cariello A; Aprile G; Renne M; Bonanni B; DeCensi A
J Clin Oncol; 2023 Jun; 41(17):3116-3121. PubMed ID: 36917758
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial.
Serrano D; Gandini S; Thomas P; Crew KD; Kumar NB; Vornik LA; Lee JJ; Veronesi P; Viale G; Guerrieri-Gonzaga A; Lazzeroni M; Johansson H; D'Amico M; Guasone F; Spinaci S; Bertelsen BE; Mellgren G; Bedrosian I; Weber D; Castile T; Dimond E; Heckman-Stoddard BM; Szabo E; Brown PH; DeCensi A; Bonanni B
JAMA Oncol; 2023 May; 9(5):664-672. PubMed ID: 36951827
[TBL] [Abstract][Full Text] [Related]
20. Novel routes for administering chemoprevention: local transdermal therapy to the breasts.
Lee O; Khan SA
Semin Oncol; 2016 Feb; 43(1):107-115. PubMed ID: 26970129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]